Liquidia (NASDAQ:LQDA) Insider Sanjeev Khindri Sells 1,101 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,101 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $28.48, for a total value of $31,356.48. Following the sale, the insider owned 64,846 shares of the company’s stock, valued at $1,846,814.08. This represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Price Performance

LQDA stock opened at $26.81 on Wednesday. The firm’s 50-day moving average price is $63.40 and its two-hundred day moving average price is $61.76. Liquidia Corporation has a 12-month low of $21.94 and a 12-month high of $93.61. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 19.57 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter last year, the company posted ($0.49) earnings per share. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. As a group, equities analysts predict that Liquidia Corporation will post 2.05 earnings per share for the current year.

Institutional Trading of Liquidia

A number of institutional investors have recently made changes to their positions in the stock. WINTON GROUP Ltd bought a new stake in shares of Liquidia in the second quarter worth approximately $335,000. Arizona State Retirement System raised its holdings in shares of Liquidia by 5.4% during the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after purchasing an additional 900 shares during the last quarter. Nykredit A S bought a new position in Liquidia during the second quarter valued at approximately $177,000. Corient Private Wealth LP bought a new position in Liquidia during the second quarter valued at approximately $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Liquidia during the second quarter valued at approximately $1,236,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on LQDA shares. Zacks Research cut shares of Liquidia from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 22nd. HC Wainwright cut their price objective on shares of Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a report on Friday, October 2nd. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Piper Sandler set a $129.00 target price on shares of Liquidia in a research note on Friday, July 24th. Finally, Jefferies Financial Group upgraded shares of Liquidia to a “strong-buy” rating in a report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $83.69.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).